Biggest News Aggregation in the World
📰 Alrn News

Page 2 - Alrn News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Alrn. Real-time updates on events, politics, business and more.

Aileron Therapeutics (ALRN) Set to Announce Quarterly Earnings on Monday

Aileron Therapeutics (NASDAQ:ALRN – Get Rating) is set to issue its quarterly earnings data on Monday, March 27th. Aileron Therapeutics Trading Up 2.9 % Shares of ALRN stock opened at $1.39 on Friday. Aileron Therapeutics has a 12-month low of $1.25 and a 12-month high of $15.00. The business’s 50 day moving average is $2.13 […]
Aileron Therapeutics Inc Renaissance Technologies Securities Exchange Commission Aileron Therapeutics Get Rating Aileron Therapeutics Daily

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 39.6% in May

Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Rating) was the target of a significant decline in short interest in May. As of May 31st, there was short interest totalling 197,300 shares, a decline of 39.6% from the May 15th total of 326,900 shares. Based on an average daily volume of 350,100 shares, the days-to-cover ratio is […]
United States William Blair Morgan Stanley Aileron Therapeutics Inc Aileron Therapeutics Company Profile Get Rating Morgan Jesss Co

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Expected to Announce Earnings of -$0.09 Per Share

Brokerages predict that Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Rating) will report earnings per share (EPS) of ($0.09) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aileron Therapeutics’ earnings. Aileron Therapeutics reported earnings of ($0.06) per share in the same quarter last year, which indicates a negative year-over-year […]
United States William Blair Aileron Therapeutics Inc Aileron Therapeutics Company Profile Get Rating Zacks Investment Research Blair William Co

Aileron Therapeutics (NASDAQ:ALRN) Downgraded by Zacks Investment Research to "Sell"

Aileron Therapeutics (NASDAQ:ALRN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. […]
United States United Kingdom William Blair Aileron Therapeutics Inc Geode Capital Management Aileron Therapeutics Company Profile Get Rating

-$0.09 EPS Expected for Aileron Therapeutics, Inc. (NASDAQ:ALRN) This Quarter

Brokerages forecast that Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Rating) will report earnings of ($0.09) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aileron Therapeutics’ earnings. Aileron Therapeutics posted earnings per share of ($0.06) in the same quarter last year, which suggests a negative year over […]
United States William Blair Morgan Stanley Aileron Therapeutics Inc Geode Capital Management Zacks Investment Research

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Declines By 17.0%

Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Rating) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 153,600 shares, a drop of 17.0% from the April 15th total of 185,100 shares. Based on an average daily trading volume, of 360,700 shares, the days-to-cover ratio […]
United States William Blair Aileron Therapeutics Inc Geode Capital Management Aileron Therapeutics Company Profile Get Rating Zacks Investment Research

Aileron Therapeutics (NASDAQ:ALRN) Downgraded to "Hold" at Zacks Investment Research

Zacks Investment Research downgraded shares of Aileron Therapeutics (NASDAQ:ALRN – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in […]
United States United Kingdom William Blair Aileron Therapeutics Inc Geode Capital Management Aileron Therapeutics Company Profile Get Rating

Aileron Therapeutics' (ALRN) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aileron Therapeutics (NASDAQ:ALRN – Get Rating) in a research report released on Tuesday morning, Zacks.com reports. Separately, Zacks Investment Research raised Aileron Therapeutics from a sell rating to a hold rating in a research report on Tuesday, January 4th. Shares of NASDAQ:ALRN opened at $0.55 on […]
Aileron Therapeutics Inc Geode Capital Management Aileron Therapeutics Company Profile Get Rating Zacks Investment Research Blair William Co Acadian Asset Management

Aileron Therapeutics (NASDAQ:ALRN) Announces Quarterly Earnings Results

Aileron Therapeutics (NASDAQ:ALRN – Get Rating) released its quarterly earnings data on Monday. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08), MarketWatch Earnings reports. Shares of ALRN stock opened at $0.53 on Tuesday. The stock’s fifty day moving average is $0.43 and its 200-day moving average […]
Morgan Stanley Aileron Therapeutics Inc Geode Capital Management Aileron Therapeutics Company Profile Get Rating Zacks Investment Research Millennium Management

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science